Trial Profile
A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Adrenocortical carcinoma; Liver cancer; Pancreatic cancer; Phaeochromocytoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors INSYS Pharma
- 17 Nov 2014 Status changed from recruiting to discontinued according to the ClincalTrials.gov record.
- 17 Nov 2014 Status changed from recruiting to discontinued according to the ClincalTrials.gov record.
- 03 Sep 2014 As per NCt record, no. of tt. arms changed from 1 to 4; time points for end points are changed.